The ubiquitous metabolic intermediary and nucleoside adenosine also serves as a neuromodulator under physiological conditions (Fredholm. et al., 1994) . Growing evidence supports an important role for adenosine in modulating ischemic neuronal injury as well (Rudolphi et al., 1992; Deckert and Gleiter, 1994; Phillis, 1997; von L ubitz, 1997) . First, adenosine levels markedly increase in response to cerebral ischemia and hypoxia as ATP breakdown dramatically increases the formation of adenosine. The extracellular levels of adenosine often rise faster (within minutes), higher (by more than 50-fold), and after smaller reductions in cerebral blood flow (CBF) compared with the levels of neurotransmitters such as glutamate (Hagberg et al., 1987; Matsumoto et al., 1992) . Second, elevating extracellular adenosine levels by inhibiting adenosine degradation or uptake reduces ischemia-induced brain damage (Rudolphi et al., 1992) . Third, adenosine analogs can attenuate hypoxic -ischemic neuronal injury, whereas certain adenosine antagonists exacerbate it (Rudolphi et al., 1992; Phillis, 1997; von L ubitz, 1997) .
Although early studies suggested that adenosine acts predominantly as a neuroprotectant during cerebral ischemia (Deckert and Gleiter, 1994; Rudolphi et al., 1992) , the complexity of the role of adenosine has been increasingly appreciated with the identification of four major adenosine receptor subtypes (A 1 , A 2A , A 2B , and A 3 ), each having a unique distribution among brain regions and their neuronal, glial, and vascular elements (Fredholm et al., 1994) . Furthermore, these receptors are differentially coupled through G-protein receptors to second messengers, including cAMP and calcium (Fredholm et al., 1994 . Nevertheless, the neuroprotective effects of adenosine can be attributed at least in part to A 1 receptor stimulation, as A 1 -specific agonists and antagonists consistently attenuate and potentiate ischemic brain injury, respectively (Rudolphi et al., 1992) . A 1 receptor-mediated neuroprotection may be a result of the inhibitory action of A 1 receptors on the release of excitatory amino acids such as glutamate (Rudolphi et al., 1992) .
Much less is known about the role of A 2A receptors in ischemic damage (Phillis, 1997; von Lubitz, 1997) . A 2A receptors are expressed at high levels in the striatum (Shiffmann et al., 1991; Fink et al., 1992; Svenningsson et al., 1998) but are also present in other brain regions, such as the cortex and hippocampus (Johansson et al., 1993; Weaver, 1993; Rosin et al., 1998) , and on the endothelial and smooth muscle cells of the cerebral vasculature (Kalaria and Hank, 1986) . Efforts to clarify the role of A 2A receptors in ischemic injury have produced mixed results. The relatively specific A 2A agonist CGS 21680 reduces ischemic or excitotoxic hippocampal damage (Scheardown and Knutsen, 1996; Jones et al., 1998) . A 2A receptor-mediated vasodilation (Phillis, 1989; Ibayashi et al., 1991) , inhibition of platelet aggregation (Sandoli et al., 1994; Ledent et al., 1997) , and suppression of neutrophil superoxide generation (Cronstein, 1994; Jordan et al., 1997) may account for A 2A receptor-mediated protection. These beneficial vascular effects of A 2A receptor activation have been suggested as a partial explanation for the exacerbation of ischemic brain damage induced by the nonselective adenosine antagonists theophylline and caffeine (Rudolphi et al., 1992) . On the other hand, several relatively specific A 2A antagonists have been found to reduce ischemic damage in animal models of global or permanent ischemia, as well as in excitotoxic neuronal damage (Gao et al., 1994; Phillis, 1995; von L ubitz et al., 1995; Jones et al., 1998; Monopoli et al., 1998) . A 2A receptor-mediated facilitation of glutamate release observed in ischemic cortex Simpson et al., 1992) and striatum (Popoli et al., 1995; Corsi et al., 1997) may explain a protective effect of A 2A antagonists. Thus, the contradictory data on A 2A receptors in cerebral ischemia may reflect their potential to produce opposing effects through different (vascular and neuronal) mechanisms.
In addition, our understanding of how A 2A receptors influence ischemic injury has been confounded by the poor specificity and solubility of adenosine drugs. Almost all A 2A adenosine receptor agonists and antagonists also have some effects on A 1 or A 3 receptors (Jacobson et al., 1992; Ongini and Fredholm, 1996; Ongini et al., 1999) . To help clarif y the role that A 2A receptors play in neurological disorders such as stroke, we generated A 2A receptor knock-out (A 2A KO) mouse strains (which are distinct from a previously reported A2a KO strain) (Ledent et al., 1997) and examined the susceptibility of these mice to ischemic brain injury. We demonstrate that A 2A receptor inactivation attenuates brain damage and preserves neurological f unction after transient middle cerebral arterial (MCA) occlusion. These results strongly support the prospect that A 2A receptor blockade may offer neuroprotection against brain damage induced by transient focal ischemia.
MATERIALS AND METHODS
Generation of A 2A KO mice. Three independent genomic clones (ϳ20 kb genomic DNA fragment) encoding a putative A 2A receptor gene from a mouse 129-Steel genomic library were isolated using the rat A 2A receptor cDNA as a probe. Characterization of the mouse A 2A receptor gene revealed an additional (previously unknown) exon in the 5Ј untranslated region (Chen and Fink, 1996) (Fig. 1 A) . Based on this A 2A receptor genomic map, a standard replacement-type vector was constructed to inactivate the A 2A receptor gene. It consists of 5 and 4.5 kb of A 2A receptor genomic fragments (as the lef t and right arms of the inset, respectively) flanking a positive selection marker (PGK-Neo cassette). This target vector disrupts the A 2A receptor gene by replacing the 3Ј end of exon 2 (12 bp from the splice junction site) and the adjacent intron sequences (0.9 kb from 5Ј end of the splice junction site) with the PGK-Neo cassette. A dysf unctional mutant gene product was expected because the deleted 3Ј end of exon 2 in the mouse A 2A receptor gene corresponds to a highly conserved region of the mouse A 2A receptor between the third and fourth transmembrane domains (Peterfreund et al., 1996) .
Embryonic stem (ES) cells [129/SvJae, "Steel substrain" (Simpson et al., 1997) ] were obtained from Dr. E. Li (Li et al., 1992) in the Knockout Core Facility at Massachusetts General Hospital. The A 2A receptor targeting vector was transferred into ES cells by electroporation. Targeted ES clones were selected and expanded in medium containing the aminoglycoside antibiotic G418. Mutant clones with the desired recombinant allele were identified by Southern blotting using a nonoverlapping 3Ј probe after digestion with BamHI (at sites designated by B in Fig. 1 A) . One of the ES cell clones (#50) containing the recombinant allele was injected into blastocysts and transferred to a host in the Knockout Core Facility. Viable chimeric mice were maintained until weaning, and these chimeric mice (F0) were bred to C57BL /6 (Taconic, Germantown, N Y) or 129/SvEvTac mice [Steel substrain (Simpson et al., 1997) , Taconic]. The germ line-transmitting mice with the A 2A receptor mutation were identified by Southern blot (F1). Heterozygous female and male mice from different founder mice were interbred to generate homozygous, heterozygous, and wild-type (W T) littermates mice, which were delivered at gestation day 21 in a normal mendelian distribution of A 2A receptor genotypes. The F2-F4 generations of A 2A homozygous, heterozygous, and wild-type littermates were used here. The hybrid (C57BL /6 ϫ 129-Steel) mice were used for anatomical, immunohistochemical, and behavioral characterization of A 2A KO mice. Ischemic injury studies (including hemodynamic and other physiological measure- ments) were performed in both the hybrid (C57BL /6 ϫ 129-Steel) and pure 129-Steel strains.
Receptor autoradiography and immunohistochemistr y. Receptor autoradiography for detecting A 2A and NMDA receptors using the specific ligands 3 H-CGS 21680 (46.0 C i /mmol; N EN, Boston, M A) and 3 H-M K-801 (22.5 C i /mmol; N EN), respectively, was performed as described previously (Johansson et al., 1993) . For A 2A receptor binding, coronal brain sections were preincubated at room temperate with 50 mM Tris-HC l buffer, pH 7.7, and 1 U of adenosine deaminase for 20 min and then incubated with the Tris buffer containing 2.5 nM 3 H-CGS 21680 for 60 min. For NMDA receptor binding, the slides were preincubated in 50 mM Tris-acetate buffer twice at 4°C for 15 min each time and were then incubated with 5.0 nM 3 H-M K-801 in the presence of 30 M glutamate and 10 M glycine. To define nonspecific binding for the A 2A and NMDA receptors, 20 M of 2-chloroadenosine or 5.0 M M K-801, respectively, was coincubated in adjacent sections.
For immunohistochemistry, mice were anesthetized with Avertin (2% tribromoethanol, 1% tertiary amylalcohol) and fixed by transcardial perf usion with 4% paraformaldehyde in 0.1 M sodium cacodylate buffer, pH 7.4. The brains were post-fixed in the same solution for 2 hr and then cryoprotected in 20% glycerol. Brains were cut coronally in 25 m sections with a sliding microtome. Immunostaining was performed in free-floating sections following standard avidin -biotin procedures described previously (Moratalla et al., 1996) .
Hemodynamic and other physiolog ical measurements. All procedures, measurements, and analyses were performed in a manner blinded to A 2A receptor genotype. Adult littermate mice (male and female, weighing 18 -25 gm) were housed in the Massachusetts General Hospital Knockout Core facility under conditions of diurnal light cycling with access to food and water ad libitum. Anesthesia was induced by 2% halothane and maintained with 1% halothane in 70% N 2 O and 30% O 2 using a Fluotec 3 vaporizer (Colonial Medical). In randomly selected mice (n ϭ 6 for each group), the right femoral artery was cannulated with PE-10 polyethylene tubes for arterial blood pressure and heart rate measurement (ETH 400 transducer and MacLab/8 data acquisition system; AD Instruments) and blood gas determination using a pH / Blood Gas Analyzer (Corning 178; C iba Corning Diagnostics, Medfield, M A). Core temperature was measured using a BAT-12 thermometer (Physitemp, C lifton, NJ). Core temperature was maintained at ϳ36.5-37.0°C with a thermostat (Frederick Haer Company, Bowdoinham, M E). Because hypothermia is a well known complication of prolonged ischemia, mice were kept in an incubator (ThermoC are Systems) at 32°C and 45% humidity for 6 hr after ischemia.
Focal transient ischemia (MCA occlusion) model. Focal cerebral ischemia was induced by occlusion of the left MCA with an 8 -0 nylon monofilament (Ethicon, New Brunswick, NJ) coated with a mixture of silicone resin (Xantopren, Osaka, Japan) and a hardener (Elastomer Activator; Bayer, Etobicoke, Ontario, C anada) as described previously (Huang et al., 1994; Hara et al., 1996; Bonventre et al., 1997) . This coated filament was introduced into the internal carotid artery through the external carotid artery, up to the origin of the anterior cerebral artery to occlude the MCA and anterior cerebral artery for 2 hr. For filament withdrawal, mice were briefly reanesthetized with halothane. In randomly selected mice (n ϭ 6 for each group), cortical CBF was determined by a PF2B laser-Doppler flowmetry (Perimed, Stockholm, Sweden) and recorded on a MacLab/8 data acquisition system (AD Instruments). The tip of the probe was fixed 2 mm posterior and 6 mm lateral to bregma on the ipsilateral hemisphere. These coordinates identified the site on the convex brain surface within the vascular territory supplied by proximal segments of the MCA, and they corresponded to brain ischemic core area (Huang et al., 1994) . Steady-state baseline values were recorded before MCA occlusion. Cortical CBF was recorded continuously before, during, and after ischemia and reperf usion and was expressed as percentage relative to the baseline value.
Measurement of neurolog ical deficits and locomotion. For scoring neurological deficits, mice were ranked as described previously (Hara et al., 1996) : 0, no observable neurological deficit (normal); 1, failure to extend right forepaw (mild); 2, circling to the contralateral side (moderate); and 3, loss of walking or righting reflex (severe). The animals were rated by an observer blinded to the genotypes.
Horizontal locomotor activity was assessed in polypropylene cages that were placed into adjustable frames equipped with seven infrared photocell beams, recorded, and analyzed on a computer (San Diego Instruments, San Diego, CA). Ambulation was quantified as the number of sequential breaks in adjacent beams. Mice were habituated in the test cages for at least 120 min before recording basal locomotion for 60 min. In assessing the motor-depressant effect of CGS 21680, locomotor activity was measured during the dark phase of the light cycle to obtain high basal locomotion. CGS 21680 was administered intraperitoneally (0.1 ml /10 gm), and locomotion was recorded for an additional 60 min.
Infarct volume measurement. T wenty-two hours after reperf usion, animals were decapitated under deep halothane anesthesia, and the brains were removed. For 2,3,5-triphenyltetrazolium chloride (TTC)-stained sections, brains were sectioned coronally into five 2 mm slices in a mouse brain matrix (RBM-2000C; Activational Systems). Slices were stained with 2% TTC (Sigma, St. L ouis, MO) in PBS, followed by 10% formalin overnight. For hematoxylin -eosin stained cryostat sections, the brains were first immediately frozen in 2-methylbutane on dry ice and then sectioned coronally into 10 20-m-thick slices (from ϩ2.80 to Ϫ4.84 mm relative to bregma) in a microtome. Coronal sections were stained with hematoxylin and eosin. The infarct area (in square millimeters) of each TTC -stained section or hematoxylin -eosin-stained cryostat section was measured using an image analysis system (M4; Imaging Research, St. C atharine's, Ontario, C anada) on the posterior surface of each section. The total infarct volume was calculated by summing the volumes of the sections as described previously (Huang et al., 1994) .
RESULTS

Targeted inactivation of the A 2A receptor in homozygous mutant mice
To generate mice lacking the A 2A receptor, a gene targeting vector was constructed with 10 kb of the murine A 2A receptor gene disrupted by a positive selection marker, Neo (Fig. 1 A) . The replacement of a critical stretch of nucleotides at the junction of exon 2 and its 3Ј intron with the Neo cassette was designed to ensure that the resulting mutant gene does not encode a functional A 2A receptor. The A 2A receptor genotypes of mice generated with this vector were determined by Southern blot analysis, yielding the expected 7.5 and 5.0 kb labeled restriction fragments for wild-type and mutant alleles, respectively ( Fig. 1 A, B) . (Fig. 1 D) . Similarly, the A 2A antagonist 8-(3-chlorostyryl)caffeine (CSC) induced motor stimulation in WT mice but not in A 2A KO mice (data not shown). Together, these genetic, neurochemical, and behavioral data demonstrate the functional disruption of A 2A receptors in homozygous mutant mice. The neuropeptide enkephalin is highly colocalized with A 2A receptors in the striatopallidal projection neurons (Shiffmann et al., 1991; Fink et al., 1992; Svenningsson et al., 1998) , and thus its pattern of expression may be most sensitive to the absence of these receptors during development. The extent and distribution of enkephalin immunoreactivity appeared normal in KO mice (Fig. 2) . Enkephalin immunostaining is concentrated in the ma-trix compartment of the striatum, and this pattern is preserved in A 2A KO mice. Conversely, dynorphin is a relatively specific marker for the striosomal compartment (Graybiel, 1990) . Characteristic clusters of dynorphin-immunoreactive neurons in A 2A KO striatum were indistinguishable from those in W T mice (Fig.  2) . In addition, cortical lamination assessed by Nissl staining was indistinguishable between A 2A W T and KO mice (data not shown). These results indicate that striatal and cortical architecture appears to have developed normally in the absence of A 2A receptors.
The possibility of neurochemical adaptations to the absence of A 2A receptors in the KO mice was also considered. Because NMDA receptors play a critical role in focal ischemia-induced neuronal cell death, we measured their binding density in cortex and striatum by receptor autoradiography using 3 H-MK-801 (dizocilpine). The levels for M K-801 binding sites were relatively high in cortex and moderate in striatum, and there was no significant difference between A 2A KO mice and their W T littermate (n ϭ 5-6). The M K-801 binding densities in cortex were 856 Ϯ 84 and 747 Ϯ 37 fmol /mg tissue, and in striatum were 840 Ϯ 89 and 777 Ϯ 59 fmol /mg tissue, for A 2A KO and W T mice, respectively (Fig. 2) .
Cerebrovascular and systemic physiology are indistinguishable between A 2A KO and WT mice in the MCA occlusion ischemia model
In the A 2A KO and W T mice with hybrid genetic background (C57BL /6 ϫ 129-Steel; n ϭ 6) ( Table 1) , there were no significant differences in basal mean arterial blood pressure (M ABP) and heart rate. M ABP in unanesthetized free-moving mice (pure 129-steel strain) also did not differ between the two groups (115 Ϯ 5 and 110 Ϯ 3.7 mmHg for A 2A W T and KO mice, respectively). Furthermore, preliminary study showed no significant difference in absolute blood flow between the two groups (data not shown). To exclude the potential contribution of strain-specific genes to the phenotypes, we also measured these physiological parameters in anesthetized A 2A KO and WT mice of a pure 129-Steel substrain (Simpson et al., 1997 ). Although we detected higher basal MABP in the pure 129-Steel mice (96 Ϯ 12 and 98 Ϯ 3 mmHg for A 2A KO and WT mice, respectively) compared with the hybrid C57BL/6 ϫ 129-Steel mice (77 Ϯ 4 and 74 Ϯ 5 mmHg for A 2A KO and WT mice, respectively), there was no significant difference in MABP between A 2A KO and WT mice in either genetic background. Of note, Ledent et al. (1997) reported a hypertensive phenotype of A 2A KO mice, in contrast to the normal MABP we observed. The discrepancy in MABP may caused by the different strains of A 2A KO mice generated by Ledent et al. (1997) (hybrid CD-1 ϫ 129/Sv strain) and our group (a hybrid C57BL/6 ϫ 129-Steel strain, as well as a pure 129-Steel substrain).
Other physiological parameters that may influence ischemic injury did not differ between the two groups at any time point during the experiment. Immediately after MCA occlusion, cortical CBF decreased to ϳ20% of baseline and remained at this level during the 2 hr of ischemia (n ϭ 6) ( Table 1) . After reperfusion, cortical CBF increased to 98 -100% in both groups within 5 min. There were no significant differences in cortical CBF before, during, and after MCA occlusion between A 2A WT and KO mice with hybrid genetic background (C57BL/6 ϫ 129-Steel) (Table 1) or with pure 129-Steel genetic background (data not shown). Finally, before and after ischemia, there was also no difference in core body temperature, arterial pH, or blood gas (PaO 2 and PaCO 2 ) values of mice with a hybrid C57BL/6 ϫ 129-Steel strain (Table 1) 
A 2A receptor inactivation attenuates transient MCA occlusion-induced cerebral infarction
Twenty-two hours after reperfusion (i.e., 24 hr after onset of ischemia), total and regional (cortical and striatal) infarction was assessed by hematoxylin and eosin staining with volumetric analysis. Total infarct volume was reduced by 26% in A 2A KO (C57BL/6 ϫ 129-Steel) mice compared with their WT littermates (61.2 Ϯ 9.1 compared with 87.2 Ϯ 3.2 mm 3 , respectively; n ϭ 6; p Ͻ 0.05) (Fig. 3A) . Similarly, in pure 129-Steel mice, infarct volume was reduced by 30% in A 2A KO mice (51.0 Ϯ 4.9 mm 3 ) compared with that of their WT littermates (72.8 Ϯ 3.5 mm 3 ; p Ͻ 0.05). In a separate set of experiments, ischemic lesion volume was also determined by staining with TTC, a marker of intact cellular metabolism. A 2A KO mice (C57BL/6 ϫ 129-Steel) showed an even more pronounced (77%) reduction of total lesion volume compared with their WT littermate control (18.0 Ϯ 4.7 compared with 77.6 Ϯ 13.4 mm 3 , respectively; n ϭ 8 -9; p Ͻ 0.05). Lesion volumes appeared intermediate in size for A 2A heterozygous mice (56.1 Ϯ 20.2 mm 3 ; n ϭ 6; p Ͼ 0.05 compared with WT, and p Ͻ 0.05 compared KO mice).
Analysis of discrete infarct areas shows significant reductions in both cerebral cortex (33%) and striatum (27%) of A 2A KO mice (pure 129-Steel) when compared with the WT littermates (Fig.  3B) . Cortical infarct volumes were 51.9 Ϯ 3.1 and 35.0 Ϯ 3.6 mm 3 for A 2A WT and KO mice, respectively (n ϭ 6; p Ͻ 0.05). Striatal infarct volumes were 21.2 Ϯ 1.3 and 15.5 Ϯ 1.8 mm 3 for A 2A WT and KO mice, respectively ( p Ͻ 0.05). Furthermore, there was no significant induction of A 2A receptors in cortex or striatum 24 hr after ischemia in W T mice. In fact, receptor autoradiography showed that focal ischemia significantly reduced binding density in the ipsilateral striatum (data not shown).
A 2A receptor inactivation preserves behavioral function after ischemic injury
We also evaluated f unctional outcome after MCA occlusion. A 2A KO mice displayed significantly fewer signs of neurological deficit compared with their W T littermates 24 hr after ischemia. Neurological deficit scores, assigned by an observer blinded to genotype, were reduced by 50 -60% in A 2A KO compared with WT mice, in both hybrid C57BL /6 ϫ 129-Steel (n ϭ 6; p Ͻ 0.05) and pure 129-Steel (n ϭ 11-12; p Ͻ 0.05) genetic backgrounds (Fig. 4) .
DISCUSSION
The present study using an A 2A KO model clearly demonstrates that inactivation of the A 2A receptor protects the brain from transient focal ischemia. MCA occlusion followed by reperfusion produces significantly smaller infarct volumes and fewer neurological deficits in mice lacking the A 2A receptor. These data establish an important role for the A 2A receptor in neuroprotection against ischemic injury and advance the prospects for A 2A receptor blockade as a pharmacological strategy to reduce ischemic brain injury.
Transgenic inactivation of A 2A receptors attenuates ischemic injury
Pharmacological analyses of A 2A receptor involvement in cerebral ischemia have produced conflicting results. Nonselective antagonists caffeine and theophylline have been shown to either potentiate or attenuate ischemia-induced brain damage depending on treatment paradigm (Rudolphi et al., 1992; Jacobson et al., 1996) . Furthermore, both agonists (Scheardown and Knutsen, 1996; Jones et al., 1998) and antagonists (Phillis, 1995; Jones et al., 1998; Monopoli et al., 1998) with relative selectivity for A 2A receptors have been shown to protect against brain damage in animal models of ischemic and excitotoxic neuronal injury. These mixed results may reflect complex actions of A 2A receptor activation during ischemia, as well as the intrinsic pharmacokinetic limitations of A 2A adenosine agents. For example, CGS 21680, one of the most selective and widely used A 2A receptor agonists, displays only a 140-fold selectivity for A 2A over A 1 receptors (Jacobson et al., 1992; Ongini and Fredholm, 1996) . However, the effective concentrations of CGS 21680 used in different studies to modify neuronal death have differed by as much as 5000-fold (Scheardown and Knutsen, 1996; Jones et al., 1998) . Similarly, CSC, an A 2A receptor antagonist frequently used to explore the Cerebrovascular and systemic physiology before, during, and after MCA occlusion-induced ischemia in A 2A wild-type and knock-out mice
Mean arterial BP (mmHg)
Cortical blood flow (%) Heart rate (beats/min)
Blood gas analysis effects of A 2A receptor blockade on ischemic damage, possesses high A 2A over A 1 receptor selectivity but displays poor solubility and C NS permeability, and it rapidly photoisomerizes to an inactive form (Ongini and Fredholm, 1996) . These pharmacological limitations are overcome by genetic deletion of the A 2A receptor, leading to complete and selective inactivation of the A 2A receptor in A 2A KO mice. Thus, attenuation of MCA occlusion-induced cerebral infarction and neurological disability in A 2A KO mice provides the strongest evidence to date that blockade of the A 2A receptor reduces ischemic damage. Together with previous demonstrations of A 2A antagonist-induced protection from global or permanent ischemia, the neuroprotection observed in a transient focal ischemia model in A 2A KO mice advances the prospects for pharmacological intervention in ischemic stroke by blocking A 2A receptors. Despite their important advantages, transgenic models raise unique considerations that must be addressed to properly interpret the data they generate (Silva et al., 1997) . Most critically, a potential contribution of genetic background to a KO phenotype must be ruled out before the phenotype can be definitely attributed to the disruption of the "knocked-out" gene (Banbury Conference on Genetic Background in Mice, 1997). Transgenic studies of neuroprotection may be particularly susceptible to misinterpretation because of differences in genetic background (Schauwecker and Steward, 1997) . In the present study, the attenuation of ischemic brain damage observed in A 2A KO mice on a standard hybrid genetic background (C57BL/6 ϫ 129-Steel) was confirmed in separately derived A 2A KO mice of a pure 129-Steel substrain. This result verifies A 2A receptor inactivation as the basis for neuroprotection from cerebral ischemia in A 2A KO mice.
Also in contrast to pharmacological approaches, an A 2A receptor KO model does not readily distinguish between developmental, chronic, and acute effects of receptor inactivation. The detection of A 2A receptor mRNA in the CNS as early as embryonic day 15 in rats (Weaver, 1993) raises the possibility that brain development could be altered in A 2A KO mice such that their predisposition to ischemic injury is reduced. Similarly, chronic A 2A receptor antagonism may lead to upregulation of other receptors such as the A 1 receptor, which can itself attenuate ischemic injury. Indeed, neuroprotection offered by chronic treatment with the nonselective adenosine antagonist caffeine has been attributed to upregulation of A 1 receptors (Jacobson et al., 1996) .
We found no evidence for contributing developmental or chronic changes in relevant anatomical and neurochemical systems. Vascular and parenchymal brain structures that we assessed were indistinguishable between A 2A KO and WT mice. Nissl staining and neuropeptide immunohistochemistry demonstrate normal laminar and compartmental patterns of cortical and striatal organization, respectively. Focal ischemic injury can be reduced by the NMDA receptor antagonist MK-801 (Pulsinelli et al., 1993) and the A 1 receptor agonist CHA (Rudolphi et al., 1992; von Lubitz, 1997) . However, we demonstrated normal tritiated MK-801 binding density (Fig. 2C ) and found no evidence for upregulation of A 1 receptor binding site density using the tritiated A 1 receptor ligands N 6 cyclohexyladenosine (CHA) and 1,3-dipropyl-8-cyclopentylxanthine (J.-F. Chen and M. A. Schwarzschild, unpublished observations (Jones et al., 1998) , neonatal hypoxia-ischemia (Bona et al., 1997) , and cerebral ischemia (Monopoli et al., 1998) . Monopoli et al. (1998) , for example, found that low doses of the A 2A receptor antagonist SCH 58261 (which binds A 2A receptors with 500-fold greater affinity than A 1 receptors) significantly reduces cortical infarction volume, even when administered 10 min after MCA occlusion. These emerging data are consistent with an acute effect of A 2A receptor deficiency in the neuroprotection observed in A 2A KO mice.
Multiple mechanisms may underlie the neuroprotection offered by A 2A KO mice
The apparent contradictions of published data on the A 2A receptor in neuroprotection point not only to the shortcomings of A 2A receptor pharmacology but also to the complexity of A 2A receptor biology. Indeed, multiple mechanisms, involving neuronal, vascular, and microglial elements, may underlie protection from cerebral ischemia offered by A 2A receptor deficiency in A 2A KO mice.
A neuronal basis for A 2A receptor modulation of ischemic injury has been suggested by studies showing adenosinergic regulation of glutamate and aspartate release. A massive release of these excitatory amino acids during brain ischemia plays a critical role in subsequent neuronal death. A 1 receptor stimulation attenuates this release and in this way likely attenuates ischemic damage (Rudolphi et al., 1992; von L ubitz, 1997) . Conversely, A 2A receptor agonists enhance the release of glutamate under ischemic and nonischemic conditions Simpson et al., 1992; Popoli et al., 1995) , as well as the release of other neurotransmitters such as acetylcholine (Sebastiao and Ribeiro, 1996; Dunwiddie and Fredholm, 1997) . To the extent that the inhibition of release by the A 1 receptor can be attributed to its negative coupling to calcium influx and /or cAM P production (Fredholm et al., 1994 , the enhancement of neurotransmitter release by the A 2A receptor may be caused by its positive coupling to these second messenger systems (Gubitz et al., 1996; Fredholm et al., 1997) . Thus, a pharmacological blockade or transgenic deficiency of the A 2A receptor may afford neuroprotection after ischemia because of reduced glutamate release and excitotoxicity.
Interestingly, the prominence of cortical as well as subcortical (striatal) protection from ischemia in A 2A KO mice belies the intense localization of brain A 2A receptors to the striatum (Fig.  1C) . This apparent mismatch of regional protection and receptor density may be explained by the ability of the relatively sparse but well documented cortical A 2A receptors to markedly enhance glutamate release (Johansson et al., 1993; Sebastiao and Ribeiro, 1996; Dunwiddie and Fredholm, 1997) . Evidence that these relatively low levels of A 2A receptor are in fact sufficient for potentiating neurotransmitter release is provided by demonstrations of A 2A receptors agonist-induced release in cortical (synaptosomal and slice) preparations (Sebastiao and Ribeiro, 1996; Dunwiddie and Fredholm, 1997 A vascular basis for the anti-ischemic phenotype of A 2A KO mice might also explain the widespread cerebral protection (i.e., far beyond the high density of neuronal A 2A receptors in striatum). A 2A adenosine agents are well known for their vasoactive properties (Phillis, 1989; Ibayashi et al., 1991) , which result from the functions of A 2A receptors located on cerebral, as well as systemic, vasculature (Kalaria and Hank, 1986) . However, activation of A 2A receptors on cerebral vascular smooth muscle and endothelial cells produces vasodilatation and thus may increase cerebral blood flow (Phillis, 1989; Ibayashi et al., 1991) . Indeed, under hypoxic conditions, cortical blood flow is enhanced by the A 2A receptor agonist CGS 21680 and is reduced by the specific A 2A receptor antagonist Z M 241385 (Coney and Marshall, 1988) . Hence, the pharmacological data would not predict a vascular mechanism of attenuated ischemic damage in A 2A KO mice. Moreover, direct comparison of cerebral blood flow and systemic cardiovascular parameters showed no difference between A 2A KO and W T mice before, during, or after MCA occlusion.
A 2A receptor activation also regulates the aggregation of platelets and the generation of reactive oxygen species, which may participate in the development of ischemic injury. Again however, A 2A receptor pharmacology would suggest that these functions do not contribute to the cerebroprotective phenotype of A 2A KO mice. A 2A receptor agonists have been shown to inhibit platelet aggregation (Sandoli et al., 1994; Ledent et al., 1997) and free radical generation by neutrophils (Cronstein, 1994; Jordan et al., 1997) . Thus, A 2A receptor inactivation may be expected to enhance platelet initiation of vascular occlusion and neutrophiltriggered oxidative damage, neither of which would account for the observed reduction in infarct size in mice lacking the A 2A receptor. Furthermore, in our study, all other physiological parameters assessed for their potential contribution to ischemic injury (body temperature and blood pH, oxygenation and CO 2 content) were indistinguishable between KO and WT mice, both before and after ischemia. Together with previously published A 2A receptor pharmacology, the physiological and anatomical data reported here argue against a vascular mechanism underlying the neuroprotection seen in A 2A KO mice. Because of offsetting vascular actions of A 2A receptors, the potential for neuroprotection by A 2A receptor inactivation may be significantly underestimated. Selective blockade of neuronal A 2A receptors may therefore provide further protection against transient focal ischemia in brain than was observed in A 2A KO mice.
In conclusion, the A 2A KO model presented here demonstrates that A 2A receptor deficiency attenuates cerebral damage and dysfunction induced by transient focal ischemia and suggests that A 2A receptor stimulation may normally exacerbate cerebral infarction. Together with the well established protective effect of A 1 receptor stimulation, our data support a more refined view of adenosine signaling in ischemic brain injury. The high levels of extracellular adenosine in ischemic brain tissues may trigger offsetting A 1 and A 2A receptor effects on neurotoxicity, possibly through opposing influences on glutamate release. The marked preservation of neurological f unction associated with attenuated cerebral infarction in A 2A KO mice highlights the potential benefit of A 2A receptor antagonists in the treatment of ischemic stroke. Moreover, the proposed model encourages the rational development of neuroprotective strategies involving potentially additive or synergistic effects of A 2A receptor blockade combined with A 1 receptor stimulation.
